US Patent

US9155705 — DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation

Formulation · Assigned to Boehringer Ingelheim International GmbH · Expires 2030-05-21 · 4y remaining

Vulnerability score 48/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects pharmaceutical compositions that combine a DPP-4 inhibitor with another antidiabetic agent in a fixed dose, specifically in tablet form.

USPTO Abstract

The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases.

Drugs covered by this patent

Patent Metadata

Patent number
US9155705
Jurisdiction
US
Classification
Formulation
Expires
2030-05-21
Drug substance claim
No
Drug product claim
Yes
Assignee
Boehringer Ingelheim International GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.